Morgan Stanley equity strategists picked nine stocks they believe could be near-term movers in the early weeks of earnings season, either due to earnings or other developments.
One of those is Goldman, which could post better-than-expected on revenues, they believe.
Morgan Stanley analyst Betsy Graseck said her revenue forecast is five percent above the consensus, and while she sees revenue from fixed income, currencies and commodities declining by 27 percent, she believes it is already “baked into the stock.” The quarter has a tough comparison to last year, but the 19 percent jump in oil prices could help drive an upside surprise, she notes. Stronger stock markets should help trading and investing and lending revenues.
The stock could also see the added benefit of deregulation. Fed Vice Chair of Supervision Randy Quarles was confirmed last week, and Joseph Otting, former OneWest CEO, is likely to be confirmed in the next several weeks to run the Office of the Comptroller of Currency. Four of seven “key regulatory positions will be filled by nominees from the new administration, paving the way for deregulation to accelerate,” Graseck wrote.
Goldman, she says, is the cheapest way to play the deregulation theme since it is less pricey than the money center banks on a price-earnings basis. The company has targeted $900 million in cost cuts and seeks to drive its expense ratio lower from 66 percent in 2016 to 62 percent in 2018.
GE, on the other hand, could see a rare earnings miss, says Morgan Stanley analyst Nigel Coe. Coe said GE could miss versus the consensus due to its power and aviation results.
“We also expect FY guidance to come under pressure on a revised outlook for flattish power” unit results, which the consensus sees up five to 10 percent, Coe noted. He also sees pressure at aviation and shortfalls in energy and transportation segments.
Coe says he agrees with the bears that GE has “deteriorating cash flow, low earnings quality, persistent downside and no clear break-up value.” There will likely be revisions to 2018 expectations but he adds earnings can grow past 2018 with improved growth in aviation, health care and renewables through 2020.
Among the stocks on Morgan Stanley’s potential list of earnings season winners are Alexion Pharmaceuticals which may miss on Solaris revenues but could get approval for extending the drug’s use. The FDA PFUDA data is Oct. 23 and could drive the stock “materially higher and more than offset the weak quarter,” the firm notes. Margins are also improving as a new, experienced management team takes charge.
Stocks that may stumble during earnings include Amgen, Group 1 Automotive and Popular Inc, according to the note. On Amgen, Morgan Stanley said the earnings could be weak on concerns about Enbrel, which is 25 percent of revenues. Morgan Stanley, however, is overweight Amgen and believes there will be upside form its pipeline and recent launches.